NervGen Pharma Corp. (TSXV:NGEN)
Canada · Delayed Price · Currency is CAD | Market Cap | 410.19M +110.1% |
| Revenue (ttm) | n/a |
| Net Income | -25.57M |
| EPS | -0.36 |
| Shares Out | 79.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 66,939 |
| Open | 4.95 |
| Previous Close | 5.00 |
| Day's Range | 4.93 - 5.23 |
| 52-Week Range | 2.57 - 8.49 |
| Beta | 0.86 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 2, 2026 |
About NervGen Pharma
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer’s disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement wi... [Read more]
Financial Performance
Financial StatementsNews
NervGen Pharma (NGEN) Advances RESTORE Study with FDA Backing, Faces Valuation Challenges
NervGen Pharma (NGEN) Advances RESTORE Study with FDA Backing, Faces Valuation Challenges
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates
Site activation and screening for the Phase 3 RESTORE study is expected to begin in September 2026, with the first participant anticipated to be dosed shortly thereafter. Strengthened leadership team,...
NervGen Pharma (NGEN) Receives Buy Rating from TD Cowen, Shares Rally
NervGen Pharma (NGEN) Receives Buy Rating from TD Cowen, Shares Rally
NervGen Pharma (NGEN) Reports Promising Gait Analysis Results
NervGen Pharma (NGEN) Reports Promising Gait Analysis Results
NervGen Pharma (NGEN) Launches $60 Million Public Offering of Shares and Warrants
NervGen Pharma (NGEN) Launches $60 Million Public Offering of Shares and Warrants
NervGen Prices $60 Mln Offering Of Shares And Warrants To Advance NVG-291; Stock Down
(RTTNews) - NervGen Pharma Corp. (NGEN), a clinical-stage biopharmaceutical company, priced the public offering of 24 million shares and accompanying warrants to purchase up to 24 million shares at $2...
NervGen Pharma (NGEN) Announces Secondary Offering Price Range
NervGen Pharma (NGEN) Announces Secondary Offering Price Range
NervGen Pharma (NGEN) Launches Public Offering of Shares and Warrants
NervGen Pharma (NGEN) Launches Public Offering of Shares and Warrants
NervGen Pharma (NGEN) Advances Phase 3 Study for Tetraplegia Treatment
NervGen Pharma (NGEN) Advances Phase 3 Study for Tetraplegia Treatment
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
Completed End-of-Phase 2 meeting with the FDA; Company expects to provide a regulatory update in early 2Q 2026 and remains on track to initiate a Phase 3 study in chronic tetraplegia in mid-2026. Comp...
NervGen Pharma (NGEN) to Voluntarily Delist from TSX Venture Exchange
NervGen Pharma (NGEN) to Voluntarily Delist from TSX Venture Exchange
NervGen Pharma to Participate at Upcoming Investor Conferences
VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing firs...
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams
VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing firs...
NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium
Adam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical data from the Phase 1b/2a CONNECT SCI Study demonstrating durable improvement in function, independenc...
NervGen Pharma Appoints Adam Rogers As CEO
(RTTNews) - NervGen Pharma Corp. (NGEN), Monday announced the appointment of Adam Rogers as President and Chief Executive Officer of the company, effective immediately.
NGEN: NervGen Pharma Appoints New CEO to Advance NVG-291
NGEN: NervGen Pharma Appoints New CEO to Advance NVG-291
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury
VANCOUVER, British Columbia, Feb. 09, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing fi...
NervGen Pharma Debuts On Nasdaq
(RTTNews) - NervGen Pharma Corp., (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biopharmaceutical company developing neuroreparative therapeutics for spinal cord injury and other neurotraumatic and ne...
NervGen Pharma Begins Trading on Nasdaq Today
VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing firs...
NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing...
NervGen Pharma Announces Proposed Amendment to Warrants
Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing...
NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates
Expanded CONNECT SCI Study data demonstrated unprecedented durable improvement in function, independence, and quality of life in individuals living with chronic spinal cord injury Completed a U.S. Foo...
NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury
Week 16 follow-up data, coupled with blinded exit interviews conducted up to 364 days after the study period, confirm durable and wide-ranging upper and lower-body improvements compared to placebo Par...
NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
Vancouver, British Columbia--(Newsfile Corp. - November 19, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing...